Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

Oral PCSK9 Inhibitor Lowering Cholesterol in First Human Trial

News | Pharmaceuticals

Oral PCSK9 Inhibitor Safe and Effective in Lowering Cholesterol in First Human Trial

November 19, 2021 — Results from two early clinical studies show the first version of an oral PCSK9-inhibitor ...

November 19, 2021

Coronary Artery Bypass Grafting (CABG). #AHA21

News | Cardiovascular Surgery

Moderna Announces Positive Data from Phase 2 Study of mRNA VEGF-A in Patients Undergoing CABG

November 18, 2021 — Moderna Inc. announced positive data from the AstraZeneca-led Phase 2 (EPICCURE) study evaluating ...

November 18, 2021

Cardiovascular Surgery Ticagrelor - significant increase in bleeding when people had bypass surgery after two to three days of discontinuing ticagrelor. #AHA #AHA21

News | Cardiovascular Surgery

Time From Stopping Blood Thinner To Bypass Surgery May Be Shortened for Select Patients

November 18, 2021 — People who are on the antiplatelet medication ticagrelor and need coronary artery bypass surgery may ...

November 18, 2021

Taking daily low-dose aspirin for seven years did not affect the risk of dementia or mental decline among adults with type 2 diabetes, according to the late-breaking ASCEND study presented at the American Heart Association’s Scientific Sessions 2021. Type 2 Diabetes and Aspirin Regimen. #AHA

News | Antiplatelet and Anticoagulation Therapies

Long-term, Low-dose Aspirin Did Not Affect Risk of Dementia in Adults With Type 2 Diabetes

November 17, 2021 — Taking daily low-dose aspirin for seven years did not affect the risk of dementia or mental decline ...

November 17, 2021

Canagliflozin, a medication used to treat type 2 diabetes, was found to greatly improve symptoms and quality of life within 3 months for people with heart failure due to either reduced or preserved cardiac function, even if they didn’t also have type 2 diabetes, according to the late-breaking CHIEF-HF study presented at the American Heart Association’s Scientific Sessions 2021. Type 2 Diabetes Canagliflozin 100mg Tablet.

News | Heart Failure

Heart Failure Symptoms Improved With a Type 2 Diabetes Medicine in Fully Remote Trial

November 17, 2021 — Canagliflozin, a medication used to treat type 2 diabetes, was found to greatly improve symptoms and ...

November 17, 2021

News | Pharmaceuticals

Bempedoic Acid Alone Lowered LDL-C Levels Comparable to Moderate or High-intensity Statin

November 15, 2021 — Esperion announced the presentation of three abstracts highlighting Nexletol tablets at the American ...

November 15, 2021

News | Pharmaceuticals

Inclisiran Reduced LDL-C in Obese Patients

November 15, 2021 — Novartis announced results from a pooled post-hoc analysis of Phase III ORION-9, -10 and -11 trials ...

November 15, 2021

Antiplatelet Plavix (Clopidogrel). OPT-PEACE trial found that nearly all patients receiving antiplatelet therapy developed evidence of abnormal gastrointestinal (GI) mucosal findings on capsule endoscopy. GettyImages

News | Antiplatelet and Anticoagulation Therapies

Most PCI Patients on Antiplatelet Therapy Developed Abnormal Gastrointestinal Findings

November 9, 2021 — Utilizing a magnetically-controlled capsule endoscopy system, the double-blind, randomized OPT-PEACE ...

November 09, 2021

A Johns Hopkins Medicine study of nearly 4,500 patients hospitalized with COVID-19 suggests that statins — medications widely used to control cholesterol — are not helpful in reducing COVID-related mortality or the severity of the illness. Graphic created by M.E. Newman, Johns Hopkins Medicine

News | Coronavirus (COVID-19)

Statins Likely Not Helpful In Reducing COVID Mortality or Severity

November 5, 2021 — In the worldwide effort to battle COVID-19 (SARS-CoV-2), researchers have often turned to medications ...

November 05, 2021

Katherine Fornell, age 5, from suburban Chicago, receives her first dose of the COVID-19 vaccine during the first week it became available in the U.S. The FDA authorized the emergency use of the Pfizer-BioNTech COVID-19 vaccine Oct. 29 for the prevention of COVID-19 in children 5 to 11 years of age. This was based on a safety review of more than 3,000 patients receiving the vaccine ages 5-11.

Feature | Coronavirus (COVID-19)

FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Children Ages 5-11

November 5, 2021 — The U.S. Food and Drug Administration (FDA) authorized the emergency use of the Pfizer-BioNTech COVID ...

November 05, 2021

Feature | Pharmaceuticals | By Dave Fornell, DAIC Editor

Draft Recommendations Suggest Not Using Aspirin for Prevention in Many Patients

There has been debate in recent years over balancing the risks vs. benefits of aspirin for the prevention of heart ...

October 13, 2021

$FDA Grants Empagliflozin Breakthrough Therapy Status for Heart Failure With Preserved Ejection Fraction. he U.S. Food and Drug Administration (FDA) recently granted the breakthrough therapy designation for empagliflozin (Jardiance) as an investigational treatment for adults with heart failure with preserved ejection fraction (HFpEF).$

News | Pharmaceuticals

FDA Grants Empagliflozin Breakthrough Therapy Status for Heart Failure With Preserved Ejection Fraction

October 7, 2021 – The U.S. Food and Drug Administration (FDA) recently granted the breakthrough therapy designation for ...

October 07, 2021

$A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line at the European Society of Cardiology (ESC) 2021 Congress, and was published in the New England Journal of Medicine. Data from the EMPEROR-Preserved and in EMPEROR-Reduced trials.$

News | Heart Failure

Empagliflozin Benefits Heart Failure Patients With Reduced and Preserved Ejection Fraction

October 1, 2021 — A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in ...

October 04, 2021

News | Antiplatelet and Anticoagulation Therapies

MASTER DAPT Shows 1-month Dual Antiplatelet Therapy After Stent Benefits High Bleeding Risk Patients

October 4, 2021 — One month of dual antiplatelet therapy (DAPT) following stent implantation in high bleeding risk ...

October 04, 2021

News | Coronavirus (COVID-19)

COVID Long-hauler Symptoms May be Caused by Antibody Attacks on ACE2

September 28, 2021 — A research team at the University of Arkansas for Medical Sciences (UAMS) has identified a ...

September 28, 2021